Metadon Abcur (Methadone Hydrochloride)

Methadone hydrochloride is a full agonist at the μ‑opioid receptors in the brain and spinal cord. Activation of these receptors produces analgesia and reduces the hyper‑activity of the opioid system that causes withdrawal, thereby stabilizing patients on opioid substitution regimens and relieving pain.

The dose of Metadon Abcur is individualized by the prescribing clinician based on the patient’s clinical condition, prior opioid exposure, and response to therapy. Dosage adjustments are made according to therapeutic goals, tolerability, and any relevant laboratory or cardiac monitoring results.

Safety data for methadone use in pregnancy and lactation are limited, and the drug is classified as a potential risk. It may be used when the benefit to the mother outweighs potential fetal or infant risks, but clinicians should discuss alternatives and closely monitor both mother and child.

To order Metadon Abcur, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both methadone (Metadon Abcur) and buprenorphine are used for opioid dependence, but methadone is a full μ‑opioid agonist with a longer half‑life, offering more stable plasma levels, whereas buprenorphine is a partial agonist with a ceiling effect on respiratory depression. Choice depends on patient history, treatment setting and risk‑benefit assessment.

Metadon Abcur should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Metadon Abcur is administered orally, typically as a tablet or liquid taken with water. The exact formulation and dosing schedule are determined by the prescriber, who may adjust the regimen based on therapeutic response and tolerability.

The most serious risks include respiratory depression, especially during dose initiation or when combined with other depressants, and cardiac arrhythmias related to QT interval prolongation. Patients should be monitored for signs of overdose, severe hypotension, seizures, and allergic reactions.

Metadon Abcur is contraindicated in individuals with known hypersensitivity to methadone, those with severe respiratory insufficiency, uncontrolled severe asthma, or significant cardiac conduction abnormalities. Caution is also advised for patients with severe hepatic impairment or those taking interacting medications that cannot be safely managed.